Latest News and Press Releases
Want to stay updated on the latest news?
-
- Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals – AUSTIN, Texas, June 14, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc....
-
- Virtual Panel to be Held on Wednesday, May 26th, 11:00am Eastern Time - - Discussion to be Moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group - AUSTIN, Texas, May 24,...
-
AUSTIN, Texas, May 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been awarded...
-
- Randomized, Controlled Study is Designed to Evaluate Cognition in Patients Who Continue Versus Discontinue Simufilam Over Six Months – - Target Enrollment is 100 Study Participants - AUSTIN,...
-
AUSTIN, Texas, April 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been...
-
Cassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation Forum
AUSTIN, Texas, April 26, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been...
-
- 9 Month Interim Analysis of Open-label Study to be Presented at a Major Scientific Conference in July 2021 as an Oral Presentation - - Initiation of Pivotal Phase 3 Program Remains On-track for 2nd...
-
AUSTIN, Texas, March 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for...
-
AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, today announced...
-
AUSTIN, Texas, March 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been...